

ENDO PHARMA LLC
Form 4
December 02, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
ENDO PHARMA LLC

2. Issuer Name **and** Ticker or Trading
Symbol
ENDO PHARMACEUTICALS
HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
320 PARK AVENUE
(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
11/29/2005

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

NEW YORK, NY 10022

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
Common Stock, par value \$.01 per share	11/29/2005		X		5,030	D \$ 2.42	20,580,002 D
Common Stock, par value \$.01 per share	11/29/2005		X		7,968	D \$ 2.42	20,572,034 D
Common Stock, par value \$.01 per share	11/29/2005		X		14,107	D \$ 2.42	20,557,927 D

Edgar Filing: ENDO PHARMA LLC - Form 4

Common Stock, par value \$.01 per share	11/29/2005	X	6,172	D	\$ 2.42	20,551,755	D
Common Stock, par value \$.01 per share	11/29/2005	X	11,288	D	\$ 2.42	20,540,467	D
Common Stock, par value \$.01 per share	11/29/2005	X	22,150	D	\$ 2.42	20,518,317	D
Common Stock, par value \$.01 per share	11/29/2005	X	8,440	D	\$ 3	20,509,877	D
Common Stock, par value \$.01 per share	11/29/2005	X	957	D	\$ 3	20,508,920	D
Common Stock, par value \$.01 per share	11/29/2005	X	5,881	D	\$ 3	20,503,039	D
Common Stock, par value \$.01 per share	11/29/2005	X	6,367	D	\$ 3.42	20,496,672	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number

Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	5,030	10/13/2005	08/26/2007	Common Stock	5,030
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	7,968	10/13/2005	08/26/2007	Common Stock	7,968
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	14,107	10/13/2005	08/26/2007	Common Stock	14,107
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	6,172	10/13/2005	08/26/2007	Common Stock	6,172
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	11,288	10/13/2005	08/26/2007	Common Stock	11,288
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	22,150	10/13/2005	08/26/2007	Common Stock	22,150
Call Option (obligation to sell)	\$ 3	11/29/2005	X	8,440	10/13/2005	08/26/2007	Common Stock	8,440
Call Option (obligation to sell)	\$ 3	11/29/2005	X	957	10/13/2005	08/26/2007	Common Stock	957
Call Option (obligation to sell)	\$ 3	11/29/2005	X	5,881	10/13/2005	08/26/2007	Common Stock	5,881
Call Option (obligation to sell)	\$ 3.42	11/29/2005	X	6,367	10/13/2005	08/26/2007	Common Stock	6,367

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022		X		

Signatures

/s/ Jeffrey R. Black Chief Financial
Officer 12/02/2005

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.